IFNG and neoplasm: The first one constructed chimeric antigen receptor T (CAR-T) cells targeting KIT in 2013 [257], and then demonstrated that such cells were able to produce IFNγ in vitro, lysed the cultured GIST cells and inhibit tumor growth in CDX model [257].